Week 2 Symptomatic Response with Vedolizumab as a Predictive Factor in Japanese Anti-TNF α-Naive Patients with Ulcerative Colitis: A post hoc Analysis of a Randomized, Placebo-Controlled Phase 3 Trial
Conclusions: Our results indicate that vedolizumab induces a rapid symptomatic response, particularly in anti-TNF α-naive patients, and suggest that early symptomatic improvement predicts treatment response at Week 10 (NCT02039505).Digestion
Source: Digestion - Category: Gastroenterology Source Type: research
More News: Bleeding | Gastroenterology | Inflammatory Bowel Disease | Japan Health | Ulcerative Colitis